Madrigal's mid-stage success stokes Viking Therapeutics, up 27% premarket
May 31, 2018 7:28 AM ETViking Therapeutics, Inc. (VKTX)VKTXBy: Douglas W. House, SA News Editor9 Comments
- Micro cap Viking Therapeutics (NASDAQ:VKTX) is up 27% premarket on average volume in response to Madrigal Pharmaceuticals' announcement of successful 36-week results from a Phase 2 study of NASH candidate MGL-3196, a thyroid hormone receptor-beta agonist.
- Viking's NASH candidate, Phase 2-stage VK2809, has the same mechanism of action.
- Previously: Madrigal's mid-stage success with NASH candidate MGL-3196 stokes Viking Therapeutics, up 2% (Dec. 6, 2017)